Thank you for visiting the Astellas Pharma Inc. Website.
You will enter external sites beyond here.
(This link opens in a new window)
Summary of Consolidated Business Results and Forecasts [IFRS]
(million yen)
| FY2015 | FY2016 | FY2017 Forecast |
|
|---|---|---|---|
| Sales | 1,372,706 | 1,311,665 | 1,279,000 |
| Gross profit | 1,037,110 | 991,162 | - |
| R&D expenses | 225,665 | 208,129 | 218,000 |
| Core operating profit | 267,456 | 274,554 | 254,000 |
| Core profit for the year | 198,802 | 213,343 | 195,000 |
| Core earnings per share (yen) | 92.12 | 101.15 | 94.43 |
(million yen)
| FY2015 | FY2016 | |
|---|---|---|
| Total Assets | 1,799,338 | 1,820,901 |
| Total equity | 1,259,209 | 1,271,810 |
| Ratio of owners' equity to gross assets (%) | 70.0 | 69.8 |
(yen)
| FY2015 | FY2016 | FY2017 Forecast |
||
|---|---|---|---|---|
| Exchange rate (Yearly average) |
US$ | 120 | 108 | 110 |
| Euro | 133 | 119 | 120 | |
Graphs of Consolidated Business Results and Forecasts [IFRS]
